Kelly Martin, Radius Health CEO
Radius rockets higher as Kelly Martin boasts of a big PhIII success — but the spoils belong to Menarini
Radius Health stuck with some fuzzy top-line Phase III results for its oral SERD therapy elacestrant, but investors saw enough to push a rally that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
